Novavax (NASDAQ:NVAX) Stock Breaks Above Fifty Day Moving Average – Time to Sell?

Novavax, Inc. (NASDAQ:NVAX)’s stock price crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $10.56 and traded as high as $10.93. Novavax shares last traded at $10.78, with a volume of 6,284,977 shares trading hands.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

Analysts Set New Price Targets

Several equities research analysts recently commented on NVAX shares. Wall Street Zen raised shares of Novavax from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a research report on Monday, November 2nd. Citigroup reaffirmed a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Novavax in a report on Friday. Finally, Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Novavax has a consensus rating of “Hold” and an average target price of $12.33.

Novavax Trading Up 10.2%

The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65. The company has a fifty day moving average price of $10.56 and a two-hundred day moving average price of $9.35.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.16. Novavax had a negative return on equity of 14.82% and a negative net margin of 18.64%. The firm had revenue of $68.30 million during the quarter, compared to analysts’ expectations of $50.42 million. During the same quarter last year, the firm earned ($1.25) earnings per share. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. As a group, equities research analysts expect that Novavax, Inc. will post -0.38 earnings per share for the current year.

Institutional Trading of Novavax

A number of hedge funds and other institutional investors have recently modified their holdings of NVAX. Russell Investments Group Ltd. increased its position in Novavax by 5.1% during the third quarter. Russell Investments Group Ltd. now owns 94,969 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 4,632 shares during the last quarter. Fulcrum Asset Management LLP purchased a new position in Novavax during the third quarter worth about $181,000. Allspring Global Investments Holdings LLC raised its stake in Novavax by 4.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 1,207 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Novavax in the 3rd quarter valued at about $91,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Novavax by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 3,926 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.